Сторінки без посилань

Наступні сторінки не містять посилань на інші сторінки цієї вікі.

Нижче показано до 50 результати у діапазоні від #11 до #60.

Переглянути (попередні 50 • наступні 50) (20 • 50 • 100 • 250 • 500).

11. (-)-p-Bromotetramisole Oxalate Enjoys Free Turbocharge... Through A Social Act Institution!
12. (-)-p-Bromotetramisole Oxalate Marketers Are Now Being Buzzed In The Us, Not Only The European Countries
13. (1999) in which the participants in these research had been described as giving
14. (1999) in which the participants in these research were described as offering
15. (1999) in which the participants in these studies had been described as offering
16. (1999) in which the participants in these studies had been described as providing
17. (1999) in which the participants in these studies had been described as supplying
18. (1999) in which the participants in these studies have been described as offering
19. (1999) in which the participants in these studies have been described as supplying
20. (1999) in which the participants in those research had been described as giving
21. (1999) in which the participants in those research had been described as offering
22. (1999) in which the participants in those research have been described as supplying
23. (1999) in which the participants in those studies had been described as giving
24. (1999) in which the participants in those studies had been described as providing
25. (1999) in which the participants in those studies have been described as delivering
26. (1999) in which the participants in those studies have been described as offering
27. (1999) in which the participants in those studies were described as giving
28. (2015), we postulate that geographic distance serves as a normally reputable proxy
29. (80.45 ) and 17 individuals 6 points (19.55 ). 5 individuals (five.74 ) created liver decompensation during antiviral therapy.
30. (80.45 ) and 17 individuals 6 points (19.55 ). 5 patients (5.74 ) developed liver decompensation in the course of antiviral therapy.
31. (80.45 ) and 17 individuals 6 points (19.55 ). 5 sufferers (5.74 ) created liver decompensation for the duration of antiviral therapy.
32. (80.45 ) and 17 individuals six points (19.55 ). 5 individuals (5.74 ) developed liver decompensation in the course of antiviral therapy.
33. (80.45 ) and 17 individuals six points (19.55 ). 5 individuals (five.74 ) developed liver decompensation for the duration of antiviral therapy.
34. (80.45 ) and 17 individuals six points (19.55 ). Five individuals (5.74 ) created liver decompensation for the duration of antiviral therapy.
35. (80.45 ) and 17 patients 6 points (19.55 ). 5 individuals (5.74 ) developed liver decompensation in the course of antiviral therapy.
36. (80.45 ) and 17 patients 6 points (19.55 ). Five individuals (five.74 ) developed liver decompensation in the course of antiviral therapy.
37. (80.45 ) and 17 patients 6 points (19.55 ). Five sufferers (5.74 ) created liver decompensation during antiviral therapy.
38. (80.45 ) and 17 patients 6 points (19.55 ). Five sufferers (5.74 ) developed liver decompensation in the course of antiviral therapy.
39. (80.45 ) and 17 patients 6 points (19.55 ). Five sufferers (five.74 ) created liver decompensation in the course of antiviral therapy.
40. (80.45 ) and 17 patients six points (19.55 ). 5 patients (five.74 ) created liver decompensation through antiviral therapy.
41. (80.45 ) and 17 patients six points (19.55 ). 5 sufferers (5.74 ) developed liver decompensation in the course of antiviral therapy.
42. (80.45 ) and 17 patients six points (19.55 ). Five sufferers (five.74 ) created liver decompensation for the duration of antiviral therapy.
43. (80.45 ) and 17 sufferers 6 points (19.55 ). 5 sufferers (five.74 ) developed liver decompensation during antiviral therapy.
44. (80.45 ) and 17 sufferers 6 points (19.55 ). Five patients (5.74 ) developed liver decompensation during antiviral therapy.
45. (80.45 ) and 17 sufferers 6 points (19.55 ). Five sufferers (five.74 ) created liver decompensation for the duration of antiviral therapy.
46. (A) Stomatal closure in wild kind Col- (white bars) and ahk5-one (black bars) leaves 2.five h soon after exposure to escalating concentrations of H2O2
47. (E) Step three uses the Gamma parameter plane spanned by the shape
48. (F) Estimation of the number of viable cells at 48 and 96 h in P19 cells taken care of with .32 M CsA throughout EB formation
49. (Figure 1D). Infections with strains carrying welldefined mutations identified to exclusively
50. (GenBank accession no. DQ389174), which was reported to have low identity
51. (GenBank accession no. DQ389174), which was reported to possess low identity
52. (N = 37), such as those encoding 13 protein
53. (Table 1). We developed a extremely sensitive search tactic combining key terms
54. (UNCH-A section) and represented by the socalledRhino-SandsofDaxner-H ketal.(2017,thisissue).The correlation
55. (along with the BDFE) of tBu3PhOH.40 The EPR equilibration process supplies
56. (as well as the BDFE) of tBu3PhOH.40 The EPR equilibration method offers
57. (aspect 1 = three.96 and factor 2 = 1.82). The two-factor structure was consistent with our theoretical
58. (mean of 3 set of experiments) in induced nNOS mRNA (column AAV
59. (sd 5 five.3). Age of onset at Wave three was obtained in two techniques
60. ), CKD (N = 261), cardiovascular (N = 578), diabetes (N = 857) and respiratory groups (N = 1156) d

Переглянути (попередні 50 • наступні 50) (20 • 50 • 100 • 250 • 500).